Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin

References

• Mareković I, Pleško S, Rezo Vranješ V, et al. Epidemiology of candidemia: three-year results from a Croatian tertiary care hospital. Journal Of Fungi. 2021;7(4):267. doi: 10.3390/jof7040267
   Web of Science ®Google Scholar
• McCarty T, White C, Pappas P. Candidemia and invasive candidiasis. Infect Dis Clin North Am. 2021;35:389–413. doi: 10.1016/j.idc.2021.03.007
   PubMed Web of Science ®Google Scholar
• Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi: 10.1038/nrdp.2018.26.
   PubMed Web of Science ®Google Scholar
• Lamoth F, Lewis RE, Kontoyiannis DP. Investigational antifungal agents for invasive mycoses: a clinical perspective. Clin Infect Dis. 2022;75(3):534–544. Erratum in: Clin Infect Dis. n;76(4):779 doi: 10.1093/cid/ciab1070
   PubMed Web of Science ®Google Scholar
• Koehler P, Stecher M, Cornely OA, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200–1212. doi: 10.1016/j.cmi.2019.04.024
   PubMed Web of Science ®Google Scholar
• Falcone M, Concia E, Iori I, et al. Identification and management of invasive mycoses in internal medicine: a road-map for physicians. Intern Emerg Med. 2014;9(5):501–511. doi: 10.1007/s11739-014-1077-4
   PubMed Web of Science ®Google Scholar
• Luzzati R, Cavinato S, Deiana ML, et al. Epidemiology and outcome of nosocomial candidemia in elderly patients admitted prevalently in medical wards. Aging Clin Exp Res. 2015;27(2):131–137. doi: 10.1007/s40520-014-0251-x
   PubMed Web of Science ®Google Scholar
• Briongos-Figuero LS, Hernanz-Román L, Pineda-Alonso M, et al. In-hospital mortality due to infectious disease in an internal medicine department. epidemiology and risk factors. Eur Rev Med Pharmacol Sci Feb. 2015;19(4):567–572.
   PubMed Web of Science ®Google Scholar
• Puig-Asensio M, Ruiz-Camps I, Fernández-Ruiz M, et al. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clin Microbiol Infect. 2015;21(5):.e491.1–.e491.10. doi: 10.1016/j.cmi.2014.12.027
   Web of Science ®Google Scholar
• Scudeller L, Bassetti M, Concia E, et al. MEDICAL group; Società Italiana di Terapia Antinfettiva (SITA); Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti (FADOI). MEDical wards Invasive Candidiasis ALgorithms (MEDICAL): Consensus proposal for management. Eur J Intern Med. 2016;34:45–53. doi: 10.1016/j.ejim.2016.07.007
   PubMed Web of Science ®Google Scholar
• Posteraro B, De Carolis E, Criscuolo M, et al. SEIFEM group. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. Mycoses. 2020;63(9):900–910. doi: 10.1111/myc.13130
   PubMed Web of Science ®Google Scholar
• Atamna A, Eliakim-Raz N, Mohana J, et al. Predicting candidemia in the internal medicine wards: a comparison with gram-negative bacteremia-a retrospectives study. Diagn Microbiol Infect Dis. 2019 Sep;95(1):80–83. Epub 2019 Apr 26. PMID: 31129007. doi: 10.1016/j.diagmicrobio.2019.04.007
   PubMed Web of Science ®Google Scholar
• Novosad SA, Fike L, Dudeck MA, et al. Pathogens causing central-line-associated bloodstream infections in acute-care hospitals-United States, 2011-2017. Infect Control Hosp Epidemiol. 2020 Mar;41(3):313–319. Epub 2020 Jan 9. PMID: 31915083. doi: 10.1017/ice.2019.303
   PubMed Web of Science ®Google Scholar
• Pieralli F, Dentali F, Giusti M, et al.; FADOI—IFI Registry Group. Clinical characteristics, management and outcome of patients with invasive candidiasis hospitalized in internal medicine units: findings from a registry by the Italian scientific society FADOI. Infection. 2021;49(2):277–285. doi: 10.1007/s15010-020-01535-z.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Vena A, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219. doi: 10.1186/s13054-019-2497-3
   PubMedGoogle Scholar
• Giacobbe DR, Magnasco L, Sepulcri C, et al. Recent advances and future perspectives in the pharmacological treatment of Candida auris infections. Expert Rev Clin Pharmacol. 2021;14(10):1205–1220. doi: 10.1080/17512433.2021.1949285
   PubMed Web of Science ®Google Scholar
• Wan Ismail WNA, Jasmi N, Khan TM, et al. The economic burden of candidemia and invasive candidiasis: a systematic review. Value Health Reg Issues. 2020 May;21:53–58.
   PubMedGoogle Scholar
• Zhao Y, Perlin DS. Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data. J Fungi (Basel). 2020;6(4):192. doi: 10.3390/jof6040192
   PubMedGoogle Scholar
• Lamoth F. Novel therapeutic approaches to invasive candidiasis: considerations for the clinician. Infect Drug Resist. 2023;16:1087–1097. doi: 10.2147/IDR.S375625
   PubMed Web of Science ®Google Scholar
• Sanchez V, Vazquez JA, Barth-Jones D, et al. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol. 1992 Nov;30(11):3005–3008. PMID: 1360476; PMCID: PMC270571. doi: 10.1128/jcm.30.11.3005-3008.1992
   PubMed Web of Science ®Google Scholar
• Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87(5):535–541.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bangard C, Jaspers NI. Hepatosplenic candidiasis. Clin Liver Dis. 2015;6(2):47–50. doi: 10.1002/cld.491
   Google Scholar
• GR T 3rd, Soriano A, Cornely OA, et al. ReSTORE trial investigators. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49–59. doi: 10.1016/S0140-6736(22)02324-8
   PubMed Web of Science ®Google Scholar
• Prigitano A, Cavanna C, Passera M. Evolution of fungemia in an Italian region. J Mycol Med. 2020;30(1):100906. doi: 10.1016/j.mycmed.2019.1009063
   PubMed Web of Science ®Google Scholar
• Adam KM, Osthoff M, Lamoth F, et al. Fungal infection network of Switzerland (FUNGINOS). Trends of the epidemiology of candidemia in Switzerland: A 15-Year FUNGINOS Survey. Open Forum Infect Dis. 2021;8(10):ofab471. doi: 10.1093/ofid/ofab471
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Trecarichi EM, Montrucchio C, et al. Mortality in patients with early- or late-onset candidaemia. J Antimicrob Chemother. 2013;68(4):927–935. doi: 10.1093/jac/dks480
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–S94. doi: 10.1093/ofid/ofy358
   PubMedGoogle Scholar
• Ko JH, Jung DS, Lee JY, et al. Changing epidemiology of non-albicans candidemia in Korea. J Infect Chemother. 2019 May;25(5):388–391. doi: 10.1016/j.jiac.2018.09.016. Epub 2018 Oct 26. PMID: 30482698.
   PubMed Web of Science ®Google Scholar
• Tan TY, Hsu LY, Alejandria MM, et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol. 54(5): Epub 2016 Feb 11. PMID: 26868904:471–477. 2016 Jul 1. 10.1093/mmy/myv114
   PubMed Web of Science ®Google Scholar
• Yamin D, Husin A, Harun A. Distribution of candidemia in Malaysian tertiary care hospital revealed predominance of Candida parapsilosis. Trop Biomed. 2020 Dec 1;37(4):903–910. PMID: 33612744. doi: 10.47665/tb.37.4.903
   PubMed Web of Science ®Google Scholar
• Mesini A, Mikulska M, Giacobbe DR, et al. Changing epidemiology of candidaemia: Increase in fluconazole-resistant Candida parapsilosis. Mycoses. 2020;63(4):361–368. doi: 10.1111/myc.13050
   PubMed Web of Science ®Google Scholar
• Castanheira M, Deshpande LM, Messer SA, et al. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination. Int J Antimicrob Agents. 2020;55(1):105799. doi: 10.1016/j.ijantimicag.2019.09.003
   PubMed Web of Science ®Google Scholar
• Soldini S, Posteraro B, Vella A, et al. Microbiologic and clinical characteristics of biofilm-forming Candida parapsilosis isolates associated with fungaemia and their impact on mortality. Clin Microbiol Infect. 2018;24(7):771–777. doi: 10.1016/j.cmi.2017.11.005
   PubMed Web of Science ®Google Scholar
• Alessandri F, Ceccarelli G, Migliara G, et al. High incidence of candidemia in critically Ill COVID-19 patients supported by veno-venous extracorporeal membrane oxygenation: a retrospective study. J Fungi (Basel). 2023;9(1):119. doi: 10.3390/jof9010119
   PubMedGoogle Scholar
• Li Y, Gu C, Yang Y, et al. Epidemiology, antifungal susceptibility, risk factors, and mortality of persistent candidemia in adult patients in China: a 6-year multicenter retrospective study. BMC Infect Dis. 2023 Jun 1;23(1):369. PMID: 37264301; PMCID: PMC10233919. doi: 10.1186/s12879-023-08241-9
   PubMed Web of Science ®Google Scholar
• Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25(7):792–798. doi: 10.1016/j.cmi.2019.03.028
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am j med. 2012;125(1 Suppl):S3–13. doi: 10.1016/j.amjmed.2011.11.001
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Prigitano A, Morroni G, et al. Candidemia: evolution of drug resistance and novel therapeutic approaches. Infect Drug Resist. 2021;14:5543–5553. doi: 10.2147/IDR.S274872
   PubMed Web of Science ®Google Scholar
• Cleary JD, Garcia-Effron G, Chapman SW, et al. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother. 2008;52(6):2263–2265. doi: 10.1128/AAC.01568-07
   PubMed Web of Science ®Google Scholar
• Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–44. Erratum in: Microbiol Immunol. 2018;62(3):205. doi: 10.1111/j.1348-0421.2008.00083.x
   PubMed Web of Science ®Google Scholar
• WHO fungal priority pathogens list to guide research, development and public health action. https://www.who.int/publications/i/item/9789240060241. [cited 27 Jun 2023]
   Google Scholar
• Desoubeaux G, Coste AT, Imbert C, et al. Overview about Candida auris: What’s up 12 years after its first description? J Mycol Med. 2022;32(2):101248. doi: 10.1016/j.mycmed.2022.101248.
   PubMed Web of Science ®Google Scholar
• Borman AM, Fraser M, Johnson EM. CHROMagarTM Candida Plus: A novel chromogenic agar that permits the rapid identification of Candida auris. Med Mycol. 2021;59(3):253–258. doi: 10.1093/mmy/myaa049
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134–140. doi: 10.1093/cid/ciw691.
   PubMed Web of Science ®Google Scholar
• O’Brien B, Liang J, Chaturvedi S, et al. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe. 2020;1(5):e193–e194. 10.1016/S2666-5247(20)30090–2. doi: 10.1016/S2666-5247(20)30090-2
   PubMedGoogle Scholar
• Ostrowsky B, Greenko J, Adams E, et al. Candida auris Isolates resistant to three classes of antifungal medications - New York, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:6–9. doi: 10.15585/mmwr.mm6901a2
   PubMed Web of Science ®Google Scholar
• Lyman M, Forsberg K, Reuben J, et al. Notes from the field: transmission of pan-resistant and Echinocandin-resistant Candida auris in health care facilities—Texas and the District of Columbia, January–April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1022–1023. doi: 10.15585/mmwr.mm7029a2
   PubMed Web of Science ®Google Scholar
• Jacobs SE, Jacobs JL, Dennis EK, et al. Candida auris pan-drug-resistant to four classes of antifungal agents. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0005322. doi: 10.1128/aac.00053-22
   PubMed Web of Science ®Google Scholar
• Mulet-Bayona JV, Salvador-García C, Tormo-Palop N, et al. Recurrent candidemia and isolation of echinocandin-resistant Candida auris in a patient with a long-term central catheter. Enferm Infecc Microbiol Clin (Engl Ed). 2022;40(6):334–335. doi: 10.1016/j.eimc.2021.04.003
   PubMedGoogle Scholar
• Ben Abid F, Salah H, Sundararaju S, et al. Molecular characterization of candida auris outbreak isolates in Qatar from patients with COVID-19 reveals the emergence of isolates resistant to three classes of antifungal drugs. Clin Microbiol Infect. 2023:S1198-743X(23)00199–4. doi: 10.1016/j.cmi.2023.04.025
   Web of Science ®Google Scholar
• Eyre DW, Sheppard AE, Madder H, et al. A candida auris outbreak and its control in an intensive care setting. N Engl J Med. 2018;379(14):1322–1331. doi: 10.1056/NEJMoa1714373
   PubMed Web of Science ®Google Scholar
• Garcia-Bustos V, Cabanero-Navalon MD, Ruiz-Saurí A, et al. What do we know about candida auris? state of the art, knowledge gaps, and future directions. Microorganisms. 2021;9(10):2177. doi: 10.3390/microorganisms9102177
   PubMed Web of Science ®Google Scholar
• Rossow J, Ostrowsky B, Adams E, et al. New york candida auris investigation workgroup. factors associated with candida auris colonization and transmission in skilled nursing facilities with ventilator Units, New York, 2016-2018. Clin Infect Dis. 2021;72(11):e753–e760. doi: 10.1093/cid/ciaa1462
   PubMed Web of Science ®Google Scholar
• Di Pilato V, Codda G, Ball L, et al. Molecular epidemiological investigation of a nosocomial cluster of C. auris: Evidence of recent emergence in Italy and Ease of Transmission during the COVID-19 Pandemic. J Fungi (Basel). 2021;7(2):140. doi: 10.3390/jof7020140
   PubMedGoogle Scholar
• Codda G, Willison E, Magnasco L, et al. In vivo evolution to echinocandin resistance and increasing clonal heterogeneity in Candida auris during a difficult-to-control hospital outbreak, Italy, 2019 to 2022. Euro Surveill. 2023;28(14). doi: 10.2807/1560-7917.ES.2023.28.14.2300161
   PubMedGoogle Scholar
• ECDC. Rapid risk assessment. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-candida-auris-outbreak-healthcare-facilities-northern-italy [cited 27 Jun 2023].
   Google Scholar
• Thatchanamoorthy N, Rukumani Devi V, Chandramathi S, et al. Candida auris: A mini review on epidemiology in healthcare facilities in Asia. J Fungi (Basel). 2022 Oct 26;8(11): 1126. PMID: 36354893; PMCID: PMC9696804. doi: 10.3390/jof8111126.
   PubMedGoogle Scholar
• Sayeed MA, Farooqi J, Jabeen K, et al. Comparison of risk factors and outcomes of Candida auris candidemia with non-Candida auris candidemia: A retrospective study from Pakistan. Med Mycol. 2020;58(6):721–729. doi: 10.1093/mmy/myz112
   PubMed Web of Science ®Google Scholar
• Simon SP, Li R, Silver M, et al. Comparative outcomes of candida auris bloodstream infections: a multicenter retrospective case-control study. Clin Infect Dis. 2023;76(3):e1436–e1443. doi: 10.1093/cid/ciac735
   PubMedGoogle Scholar
• Colombo AL, Júnior JNA, Guinea J. Emerging multidrug-resistant Candida species. Curr Opin Infect Dis. 2017;30(6):528–538. doi: 10.1097/QCO.0000000000000411
   PubMed Web of Science ®Google Scholar
• Ramos LS, Figueiredo-Carvalho MHG, Silva LN, et al. The threat called candida haemulonii species complex in rio de Janeiro State, Brazil: focus on antifungal resistance and virulence attributes. J Fungi (Basel). 2022;8(6):574. doi: 10.3390/jof8060574
   PubMedGoogle Scholar
• Mendoza-Reyes DF, Gómez-Gaviria M, Mora-Montes HM. Candida lusitaniae: biology, pathogenicity, virulence factors, diagnosis, and treatment. Infect Drug Resist. 2022 Aug 31;15:5121–5135. PMID: 36068831; PMCID: PMC9441179 10.2147/IDR.S383785
   PubMed Web of Science ®Google Scholar
• Linkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol. 1989;27(2):236–240. doi:10.1128/jcm.27.2.236-240.1989
   PubMed Web of Science ®Google Scholar
• Jung DS, Farmakiotis D, Jiang Y, et al. Uncommon Candida species fungemia among cancer patients, Houston, Texas, USA. Emerg Infect Dis. 2015;21(11):1942–1950. doi: 10.3201/eid2111.150404
   PubMed Web of Science ®Google Scholar
• Fowler SL, Rhoton B, Springer SC, et al. Evidence for person-to-person transmission of Candida lusitaniae in a neonatal intensive-care unit. Infect Control Hosp Epidemiol. 1998;19:343–345. doi: 10.2307/30141376
   PubMed Web of Science ®Google Scholar
• Asner SA, Giulieri S, Diezi M, et al. Acquired multidrug antifungal resistance in candida lusitaniae during therapy. Antimicrob Agents Chemother. 2015;59(12):7715–7722. doi: 10.1128/AAC.02204-15
   PubMed Web of Science ®Google Scholar
• Scott NE, Edwin Erayil S, Kline SE, et al.Rapid Evolution of Multidrug Resistance in a Candida lusitaniae Infection during Micafungin Monotherapy.Antimicrob Agents Chemother. 2023 Jul 10;e0054323. doi: 10.1128/aac.00543-23
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Bruun B, Christensen JJ, et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol. 2011 Jan;49(1):325–334. doi: 10.1128/JCM.01811-10
   PubMed Web of Science ®Google Scholar
• Casagrande Pierantoni D, Bernardo M, Mallardo E, et al. Candida palmioleophila isolation in Italy from two cases of systemic infection, after a CHROMagar and Vitek system misidentification as C. albicans. New Microbiol. 2020 Jan;43(1):47–50.
   PubMedGoogle Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Infectious diseases society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48(5):503–535. doi: 10.1086/596757
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444. doi: 10.3324/haematol.2016.152900
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Antonelli M, Cuenca-Estrella M, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive care Med. 2019;45(6):789–805. doi: 10.1007/s00134-019-05599-w
   PubMed Web of Science ®Google Scholar
• Grim SA, Berger K, Teng C, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2012;67(3):707–714. doi: 10.1093/jac/dkr511
   PubMed Web of Science ®Google Scholar
• Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739–1746. doi: 10.1093/cid/cis305
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25–31. doi: 10.1086/504810
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640–3645. doi: 10.1128/AAC.49.9.3640-3645.2005
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH, Kraft CS. Diagnosing Invasive Candidiasis. J Clin Microbiol. 2018;56(5):e01909–17. doi: 10.1128/JCM.01909-17
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lara MF, Ostrosky-Zeichner L. Invasive Candidiasis. Semin Respir Crit Care Med. 2020;41(1):3–12. doi: 10.1055/s-0040-1701215
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–770. doi: 10.1093/cid/ciq206
   PubMed Web of Science ®Google Scholar
• Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50(1):7–15. doi: 10.1128/JCM.05267-11
   PubMed Web of Science ®Google Scholar
• He S, Hang JP, Zhang L, et al. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: Focus on cutoff levels. J Microbiol Immunol Infect. 2015;48(4):351–361. doi: 10.1016/j.jmii.2014.06.009
   PubMedGoogle Scholar
• Posteraro B, De Pascale G, Tumbarello M, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care. 2011;15(5):R249. doi: 10.1186/cc10507
   PubMed Web of Science ®Google Scholar
• Corcione S, Chasseur L, Lupia T, et al. The DIAGNOSTIC RELEVAnce of β-D-Glucan for candidemia within internal medicine wards. Diagnostics. 2022;12(9):2124. doi: 10.3390/diagnostics12092124
   Web of Science ®Google Scholar
• Pfaller MA, Wolk DM, Lowery TJ. T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol. 2016;11(1):103–117. doi: 10.2217/fmb.15.111
   PubMed Web of Science ®Google Scholar
• Giannella M, Paolucci M, Roncarati G, et al. Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study. J Antimicrob Chemother. 2018;73(10):2856–2859. doi: 10.1093/jac/dky247
   PubMed Web of Science ®Google Scholar
• Neely LA, Audeh M, Phung NA, et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med. 2013;5(182):182ra54. doi: 10.1126/scitranslmed.3005377
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–899. doi: 10.1093/cid/ciu959
   PubMed Web of Science ®Google Scholar
• Bizerra FC, Jimenez-Ortigosa C, Souza AC, et al. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob Agents Chemother. 2014;58(4):2438–2440. doi: 10.1128/AAC.02189-13
   PubMed Web of Science ®Google Scholar
• Cuervo G, Garcia-Vidal C, Nucci M, et al. Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. Clin Microbiol Infect. 2016;22(2):181–188. doi: 10.1016/j.cmi.2015.09.029
   PubMed Web of Science ®Google Scholar
• Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43(3):235–243. doi: 10.1080/13693780410001731619
   PubMed Web of Science ®Google Scholar
• León C, Ruiz-Santana S, Saavedra P, et al. Cava Study Group. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624–1633. doi: 10.1097/CCM.0b013e31819daa14
   PubMed Web of Science ®Google Scholar
• Hermsen ED, Zapapas MK, Maiefski M, et al. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care. 2011;15(4):R198. doi: 10.1186/cc10366
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Pappas PG, Shoham S, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011;54(1):46–51. doi: 10.1111/j.1439-0507.2009.01756.x
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ933
   PubMed Web of Science ®Google Scholar
• Kato H, Hagihara M, Shibata Y, et al. Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: A systematic review and meta-analysis. J Infect Chemother. 2021;27(11):1562–1570. doi: 10.1016/j.jiac.2021.06.017
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al.; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–2029. doi: 10.1056/NEJMoa021585
   PubMed Web of Science ®Google Scholar
• Micafungin Invasive Candidiasis Working Group, Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–1527.
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007 Jun 14;356(24):2472–2482. doi: 10.1056/NEJMoa066906
   PubMed Web of Science ®Google Scholar
• Reboli AC, Shorr AF, Rotstein C, et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011;11(1):261. doi: 10.1186/1471-2334-11-261
   PubMedGoogle Scholar
• Mycoses Study Group, Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110–1122.
   PubMed Web of Science ®Google Scholar
• Kale-Pradhan PB, Morgan G, Wilhelm SM, et al. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis. Pharmacotherapy. 2010;30(12):1207–1213. doi: 10.1592/phco.30.12.1207
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Aguado JM, Almirante B, et al. CANDIPOP Project; GEIH-GEMICOMED (SEIMC); REIPI. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014;58(10):1413–1421. doi: 10.1093/cid/ciu158
   PubMed Web of Science ®Google Scholar
• Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin Infect Dis. 2021;73(11):e3647–e3655. Erratum in: Clin Infect Dis. 2021;73(3):561-562. doi: 10.1093/cid/ciaa1380
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Corcione S, Filippini C, et al. The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. Plos One. 2015;10(5):e0125149. Erratum in: PLoS One. 2015;10(6):e0131264. doi: 10.1371/journal.pone.0125149
   PubMed Web of Science ®Google Scholar
• Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. Plos One. 2015;10(3):e0120452. doi: 10.1371/journal.pone.0120452
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE Trial. Clin Infect Dis. 2019;68(12):1981–1989. doi: 10.1093/cid/ciy827
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Gutiérrez-Gutiérrez B, et al. GISA (Italian Group for Antimicrobial Stewardship). Impact of initial antifungal therapy on the outcome of patients with candidemia and septic shock admitted to medical wards: a propensity score-adjusted analysis. Open Forum Infect Dis. 2019 Jul 16: 6(7):ofz251.
   PubMed Web of Science ®Google Scholar
• López-Cortés LE, Almirante B, Cuenca-Estrella M, et al. Members of the CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect. 2016;22(8):733.e1–8. doi: 10.1016/j.cmi.2016.05.008
   PubMed Web of Science ®Google Scholar
• Rodrigues CF, Henriques M. Liposomal and deoxycholate amphotericin B formulations: effectiveness against biofilm infections of CANDIDa spp. Pathogens. 2017;6(4):62. doi: 10.3390/pathogens6040062
   PubMed Web of Science ®Google Scholar
• Sharma D, Paul RA, Rudramurthy SM, et al. Impact of FKS1 genotype on echinocandin in vitro susceptibility in candida auris and in vivo response in a murine model of infection. Antimicrob Agents Chemother. 2022;66(1):e0165221. doi: 10.1128/AAC.01652-21
   PubMed Web of Science ®Google Scholar
• Rybak JM, Barker KS, Muñoz JF, et al. In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris. Clin Microbiol Infect. 2022;28(6):838–843. doi: 10.1016/j.cmi.2021.11.024
   PubMed Web of Science ®Google Scholar
• Bidaud AL, Djenontin E, Botterel F, et al. Colistin interacts synergistically with echinocandins against Candida auris. Int J Antimicrob Agents. 2020 Mar;55(3):105901. Epub 2020 Jan 17. PMID: 31954831. doi: 10.1016/j.ijantimicag.2020.105901
   PubMed Web of Science ®Google Scholar
• Caballero U, Kim S, Eraso E, et al. In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris. Antibiotics (Basel). 2021 Mar 28;10(4):355. PMID: 33800601; PMCID: PMC8066733. doi: 10.3390/antibiotics10040355
   PubMed Web of Science ®Google Scholar
• Nagy F, Tóth Z, Nyikos F, et al. In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms. Med Mycol. 59(10): PMID: 34021571; PMCID: PMC8653632:1015–1023. 2021 Oct 4. doi: 10.1093/mmy/myab032
   PubMed Web of Science ®Google Scholar
• Balla N, Kovács F, Balázs B, et al. SynergistiC interaction of caspofungin combined with posaconazole against fks wild-type and mutant candida auris planktonic cells and biofilms. Antibiotics (Basel). 11(11): PMID: 36421245; PMCID: PMC9686983:1601. 2022 Nov 11. doi: 10.3390/antibiotics11111601
   PubMed Web of Science ®Google Scholar
• Schwarz P, Bidaud AL, Dannaoui E. In vitro synergy of isavuconazole in combination with colistin against Candida auris. Sci Rep. 2020 Dec 8;10(1):21448. PMID: 33293607; PMCID: PMC7722718. doi: 10.1038/s41598-020-78588-5
   PubMed Web of Science ®Google Scholar
• Treviño-Rangel RJ, González GM, Montoya AM, et al. Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review. J Fungi (Basel). 2022;8(11):1144. doi: 10.3390/jof8111144
   PubMedGoogle Scholar
• Wiederhold NP, Najvar LK, Olivo M, et al. Ibrexafungerp Demonstrates in vitro Activity against Fluconazole-Resistant Candida auris and in vivo Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis. Antimicrob Agents Chemother. 2021;65(6):e02694–20. doi: 10.1128/AAC.02694-20
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Shaw KJ, et al. Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis. Antimicrob Agents Chemother. 2019;63(11):e01120–19. doi: 10.1128/AAC.01120-19
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Flamm RK, et al. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019). J Glob Antimicrob Resist. 2021;26:117–127. doi: 10.1016/j.jgar.2021.04.012
   PubMed Web of Science ®Google Scholar
• Vazquez J, Reboli AC, Pappas PG, et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis. 2014;14(1):97. doi: 10.1186/1471-2334-14-97
   PubMedGoogle Scholar
• Moreno-García E, Puerta-Alcalde P, Gariup G, et al. Early Stepdown from Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. Open Forum Infect Dis. 2021;8(6):ofab250. Erratum in: Open Forum Infect Dis. 2022;9(6):ofac180. doi: 10.1093/ofid/ofab250
   PubMed Web of Science ®Google Scholar
• Soulountsi V, Schizodimos T, Kotoulas SC. Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible? Infection. 2021;49(6):1107–1131. doi: 10.1007/s15010-021-01640-7
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54(9):1240–1248. doi: 10.1093/cid/cis200
   PubMed Web of Science ®Google Scholar
• Fortún J, Meije Y, Buitrago MJ, et al. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients. J Antimicrob Chemother. 2014;69(11):3134–3141. doi: 10.1093/jac/dku225
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Ansaldi F, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive care Med. 2015;41(9):1601–1610. doi: 10.1007/s00134-015-3866-2
   PubMed Web of Science ®Google Scholar
• Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive care Med. 2020;46(11):2001–2014. doi: 10.1007/s00134-020-06240-x
   PubMed Web of Science ®Google Scholar
• Tirpack AR, Duker JS, Baumal CR. An Outbreak of Endogenous Fungal Endophthalmitis Among Intravenous Drug Abusers in New England. JAMA Ophthalmol. 2017;135(6):534–540. doi: 10.1001/jamaophthalmol.2017.0650
   PubMed Web of Science ®Google Scholar
• Haseeb AA, Elhusseiny AM, Siddiqui MZ, et al. Fungal Endophthalmitis: A Comprehensive Review. J Fungi (Basel). 2021;7(11):996. doi: 10.3390/jof7110996
   PubMedGoogle Scholar
• Venditti M. Clinical aspects of invasive candidiasis: endocarditis and other localized infections. Drugs. 2009;69(1):39–43. doi: 10.2165/11315610-000000000-00000
   PubMedGoogle Scholar
• Venditti M, De Bernardis F, Micozzi A, et al. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis. 1992;14(2):422–426. doi: 10.1093/clinids/14.2.422
   PubMed Web of Science ®Google Scholar
• Giuliano S, Guastalegname M, Russo A, et al. Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. Expert Rev Anti Infect Ther. 2017;15(9):807–818. doi: 10.1080/14787210.2017.1372749
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Stark D, Harkness J, et al. Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia. Emerg Infect Dis. 2008;14(2):327–329. doi: 10.3201/eid1402.070985
   PubMed Web of Science ®Google Scholar
• De Meo D, Cera G, Ceccarelli G, et al. Candida fracture-related infection: a systematic review. J Bone Jt Infect. 2021;6(7):321–328. doi: 10.5194/jbji-6-321-2021
   PubMedGoogle Scholar
• Majeed A, Ullah W, Zahid U, et al. Persistent spontaneous fungal peritonitis secondary to Candida albicans in a patient with alcoholic cirrhosis and review of the literature. BMJ Case Rep. 2016;2016:bcr2016216979. doi: 10.1136/bcr-2016-216979
   PubMedGoogle Scholar
• Hwang SY, Yu SJ, Lee JH, et al. Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol Infect Dis. 2014;33(2):259–264. doi: 10.1007/s10096-013-1953-2
   PubMed Web of Science ®Google Scholar
• Bassetti M, Marchetti M, Chakrabarti A, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive care Med. 2013;39(12):2092–2106. doi: 10.1007/s00134-013-3109-3
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am. 2014;28(1):61–74. doi: 10.1016/j.idc.2013.09.004
   PubMed Web of Science ®Google Scholar
• Tan WP, Turba UC, Deane LA. Renal fungus ball: a challenging clinical problem. Urologia. 2017;84(2):113–115. doi: 10.5301/uro.5000201
   PubMed Web of Science ®Google Scholar
• Ideguchi S, Yamamoto K, Ikeda A, et al. A case of bilateral emphysematous pyelonephritis caused by Candida albicans. J Infect Chemother. 2019;25(4):302–306. doi: 10.1016/j.jiac.2018.10.011
   PubMed Web of Science ®Google Scholar
• Rivoisy C, Vena A, et al; French Mycoses Study Group and Grupo de Apoyo al Manejo de las Endocarditis en España (GAMES). Prosthetic Valve Candida spp. Endocarditis: New Insights into Long-term Prognosis-The ESCAPE Study. Clin Infect Dis. 2018;66(6):825–832. doi:10.1093/cid/cix913
   PubMed Web of Science ®Google Scholar
• Falcone M, Barzaghi N, Carosi G, et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore). 2009;88(3):160–168. Italian Study on Endocarditis (SEI). doi: 10.1097/MD.0b013e3181a693f8
   PubMed Web of Science ®Google Scholar
• Russo A, Falcone M, Picciarella A, et al. Candidaemia after heart valve replacement surgery: recurrence as prosthetic valve endocarditis is an expected over one-year complication. Clin Microbiol Infect. 2016;22(5):466–467. doi: 10.1016/j.cmi.2016.01.019
   PubMed Web of Science ®Google Scholar
• Torres-Rojas JR, Stratton CW, Sanders CV, et al. Candidal suppurative peripheral thrombophlebitis. Ann Intern Med. 1982;96(4):431–435. doi: 10.7326/0003-4819-96-4-431
   PubMed Web of Science ®Google Scholar
• Caccese R, Carfagna P, Pistilli N, et al. Candidal thrombophlebitis of central veins: case report and review. Med Mycol. 2012;50(3):299–304. doi: 10.3109/13693786.2011.604046
   PubMed Web of Science ®Google Scholar
• Strinden WD, Helgerson RB, Maki DG. Candida septic thrombosis of the great central veins associated with central catheters Clinical Features And Management. Ann Surg. 1985;202(5):653–658. doi: 10.1097/00000658-198511000-00019
   PubMed Web of Science ®Google Scholar
• Tahir M, Peseski AM, SJ J. Case Report: Candida dubliniensis as a Cause of Chronic Meningitis. Front Neurol. 2020;11:601242. doi: 10.3389/fneur.2020.601242
   PubMed Web of Science ®Google Scholar
• Yamahiro A, Lau KH, Peaper DR, et al. Meningitis Caused by Candida Dubliniensis in a Patient with Cirrhosis: A Case Report and Review of the Literature. Mycopathologia. 2016;181(7–8):589–593. doi: 10.1007/s11046-016-0006-7
   PubMed Web of Science ®Google Scholar
• Fennelly AM, Slenker AK, Murphy LC, et al. Candida cerebral abscesses: a case report and review of the literature. Med Mycol. 2013;51(7):779–784. doi: 10.3109/13693786.2013.789566
   PubMed Web of Science ®Google Scholar
• Kelly L, Walsh J, Skally M, et al. Candida meningitis/ventriculitis over a decade. Increased morbidity and length of stay a concern. Br J Neurosurg. 2023;37(2):227–230. doi: 10.1080/02688697.2022.2054947
   PubMed Web of Science ®Google Scholar
• López-Dupla M, Mora Sanz P, Pintado García V, et al. Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases. Am J Gastroenterol. 1992;87(12):1771–1776.
   PubMed Web of Science ®Google Scholar
• Chen YH, Jao TM, Shiue YL, et al. Prevalence and risk factors for Candida esophagitis among human immunodeficiency virus-negative individuals. World J Clin Cases. 2022;10(30):10896–10905. doi: 10.12998/wjcc.v10.i30.10896
   PubMed Web of Science ®Google Scholar
• Candon S, Rammaert B, Foray AP, et al. Chronic Disseminated Candidiasis During Hematological Malignancies: An Immune Reconstitution Inflammatory Syndrome with Expansion of Pathogen-Specific T Helper Type 1 Cells. J Infect Dis. 2020;221(11):1907–1916. doi: 10.1093/infdis/jiz688
   PubMed Web of Science ®Google Scholar
• McLeod N, Fisher M, Lasala PR. Vertebral osteomyelitis due to Candida species. Infection. 2019;47(3):475–478. doi: 10.1007/s15010-019-01294-6
   PubMed Web of Science ®Google Scholar
• Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis. 2012;73(1):89–93. doi: 10.1016/j.diagmicrobio.2012.02.004
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Rammaert B, Brause B, et al. International Consortium for Osteoarticular Mycoses Osteoarticular Mycoses. Clin Microbiol Rev. 2022 Dec 21;35(4):e0008619. doi: 10.1128/cmr.00086-19
   PubMedGoogle Scholar
• Koutserimpas C, Zervakis SG, Maraki S, et al. Non-albicans Candida prosthetic joint infections: A systematic review of treatment. World J Clin Cases. 2019;7(12):1430–1443. doi: 10.12998/wjcc.v7.i12.1430
   PubMed Web of Science ®Google Scholar
• Vergidis P, Clancy CJ, Shields RK, et al. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. Plos One. 2016;11(4):e0153247. doi: 10.1371/journal.pone.0153247
   PubMed Web of Science ®Google Scholar
• Pea F. Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients. Expert Rev Anti Infect Ther. 2013;11(10):989–997. doi: 10.1586/14787210.2013.836058
   PubMed Web of Science ®Google Scholar
• Pappas PG. Lessons learned in the multistate fungal infection outbreak in the United States. Curr Opin Infect Dis. 2013;26(6):545–550. doi: 10.1097/QCO.0000000000000013
   PubMed Web of Science ®Google Scholar
• Wilson Dib R, Chaftari AM, Hachem RY, et al. Catheter-Related Staphylococcus aureus Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy. Open Forum Infect Dis. 2018;5(10):ofy249. doi: 10.1093/ofid/ofy249
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G. Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins. J Fungi (Basel). 2020;6(4):262. doi: 10.3390/jof6040262
   PubMedGoogle Scholar
• Adeel A, Qu MD, Siddiqui E, et al. Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report. Open Forum Infect Dis. 2021;8(11):ofab431. doi: 10.1093/ofid/ofab431
   PubMed Web of Science ®Google Scholar
• Krishnan BR, James KD, Polowy K, et al. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J Antibiot (Tokyo). 2017;70(2):130–135. doi: 10.1038/ja.2016.89
   PubMed Web of Science ®Google Scholar
• Szymański M, Chmielewska S, Czyżewska U, et al. Echinocandins - structure, mechanism of action and use in antifungal therapy. J Enzyme Inhib Med Chem. 2022;37(1):876–894. doi: 10.1080/14756366.2022.2050224
   PubMed Web of Science ®Google Scholar
• Helleberg M, Jørgensen KM, Hare RK, et al. Rezafungin in vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02438–19. doi: 10.1128/AAC.02438-19
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Meletiadis J, Zaragoza O, et al. Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method. Clin Microbiol Infect. 2018 Nov;24(11):1200–1204. doi: 10.1016/j.cmi.2018.02.021
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Carvalhaes C, Messer SA, et al. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). Antimicrob Agents Chemother. 2020 Mar 24;64(4):e00099–20. doi:10.1128/AAC.00099-20
   PubMed Web of Science ®Google Scholar
• Tóth Z, Forgács L, Locke JB, et al. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. J Antimicrob Chemother. 2019 Dec 1;74(12):3505–3510. doi: 10.1093/jac/dkz390
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Sprute R, Egger M, et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021;81(15):1703–1729. doi: 10.1007/s40265-021-01611-0
   PubMed Web of Science ®Google Scholar
• Ong V, Wills S, Watson D, et al. Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and Humans. Antimicrob Agents Chemother. 2022;66(1):e0139021. doi: 10.1128/AAC.01390-21
   PubMed Web of Science ®Google Scholar
• Ong V, Hough G, Schlosser M, et al. Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin. Antimicrob Agents Chemother. 2016;60(11):6872–6879. doi: 10.1128/AAC.00701-16
   PubMed Web of Science ®Google Scholar
• Flanagan S, Walker HE, Ong V. Coadministration of Rezafungin Does Not Impact the Pharmacokinetics of Cyclosporine, Ibrutinib, Mycophenolate Mofetil, or Venetoclax. Open Forum Infect Dis. 2022 Dec;9(Supplement_2):ofac492. doi: 10.1093/ofid/ofac492.1324
   Google Scholar
• Flanagan S, Jandourek A, Ong V, et al. Coadministration of rezafungin does not impact cyclosporine or mycophenolate mofetil pharmacokinetics. Bone Marrow Transplant. 2022;57:455–456.
   Web of Science ®Google Scholar
• Jang SM, Hough G, Mueller BA. Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy. Blood Purif. 2018;46(3):214–219. doi: 10.1159/000489212
   PubMed Web of Science ®Google Scholar
• Flanagan S, Goodman DB, Jandourek A, et al. Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects. Clin Pharmacol Drug Dev. 2020 May;9(4):456–465.
   PubMed Web of Science ®Google Scholar
• Ham YY, Lewis JS, Thompson GR. Thompson GR 3rd. Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Future Microbiol. 2021 2nd;16(1):27–36. doi: 10.2217/fmb-2020-0217
   PubMed Web of Science ®Google Scholar
• Lakota EA, Ong V, Flanagan S, et al. Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data. Antimicrob Agents Chemother. 2018;62(6):e02603–17. Erratum in: Antimicrob Agents Chemother. 2019;63(4). doi: 10.1128/AAC.02603-17
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, Andes DR. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model. Antimicrob Agents Chemother. 2019;63(11):e01556–19. doi: 10.1128/AAC.01556-19
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, VanScoy B, et al. Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. Antimicrob Agents Chemother. 2018;62(2):e02154–17. doi: 10.1128/AAC.02154-17
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, Andes DR. Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrob Agents Chemother. 2018;62(11):e01572–18. doi: 10.1128/AAC.01572-18
   PubMed Web of Science ®Google Scholar
• Lakota EA, Bader JC, Ong V, et al. Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. Antimicrob Agents Chemother. 2017;61(11):e00758–17. doi: 10.1128/AAC.00758-17
   PubMed Web of Science ®Google Scholar
• Bader JC, Lakota EA, Flanagan S, et al. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata. Antimicrob Agents Chemother. 2018;62(6):e02614–17. doi: 10.1128/AAC.02614-17
   PubMed Web of Science ®Google Scholar
• Hager CL, Larkin EL, Long LA, et al. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother. 2018;73(8):2085–2088. doi: 10.1093/jac/dky153
   PubMed Web of Science ®Google Scholar
• Bielicka I, Dickerson S, Manamley N, et al. CO89 Integrated Analysis of Efficacy and ICU Length of Stay Data from Phase 2 and Phase 3 Trials of Rezafungin for the Treatment of Invasive Candidiasis and/or Candidemia. Value Health. 2002;25(12):S35. doi: 10.1016/j.jval.2022.09.168
   Google Scholar
• Pechacek J, Yakubu I, Vissichelli NC, et al. Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient. J Antimicrob Chemother. 2022 Aug 25;77(9):2571–2573. doi: 10.1093/jac/dkac206
   PubMed Web of Science ®Google Scholar
• Melenotte C, Ratiney R, Hermine O, et al. Successful Rezafungin Treatment of an Azole-Resistant Chronic Mucocutaneous Candidiasis in a STAT-1 Gain-of-Function Patient. J Clin Immunol. 2023;43(6):1182–1184. doi: 10.1007/s10875-023-01519-2
   PubMed Web of Science ®Google Scholar
• Martini C, Torelli R, de Groot T, et al. Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital. Front Cell Infect Microbiol. 2020;10:232. doi: 10.3389/fcimb.2020.00232
   PubMed Web of Science ®Google Scholar
• Volpicelli L, Venditti M, Oliva A. Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin. Expert Rev Anti Infect Ther. 2023;21(4):329–341. doi: 10.1080/14787210.2023.2182769
   PubMed Web of Science ®Google Scholar
• Andreoni M, Bassetti M, Corrao S, et al. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021;19(9):1125–1134. doi: 10.1080/14787210.2021.1894130
   PubMed Web of Science ®Google Scholar
• Oliva A, Stefani S, Venditti M, et al. Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin. Front Microbiol. 2021;12:749685. doi: 10.3389/fmicb.2021.749685
   PubMed Web of Science ®Google Scholar
• Oliva A, Carbonara S, Cianci V, et al. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin. Expert Rev Anti Infect Ther. 2023;31:1–19. doi: 10.1080/14787210.2023.2214727
   Google Scholar